Study for AL-CM treatment in adults at one hospital
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study is looking at a treatment approach for people diagnosed with AL-CM at a specific hospital. It may help researchers understand whether the treatment is safe and effective for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old
- You have been diagnosed with AL-CM at the Second Affiliated Hospital of Zhejiang University
- You are able to understand the study and follow the study team’s instructions
- You are willing and able to complete consent forms
- You are willing to follow the study’s visit rules (you can’t be too unable or unwilling)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
Hear when a new Immunoglobulin Light Amyloidosis Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.